Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
22.1M
-
Shares change
-
+2.9M
-
Total reported value, excl. options
-
$343M
-
Value change
-
+$44.1M
-
Number of buys
-
61
-
Number of sells
-
-28
-
Price
-
$15.50
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q2 2017
104 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q2 2017.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.1M shares
of 166M outstanding shares and own 13.35% of the company stock.
Largest 10 shareholders include FMR LLC (5.51M shares), BVF INC/IL (2.03M shares), BlackRock Inc. (1.81M shares), PERCEPTIVE ADVISORS LLC (1.39M shares), VANGUARD GROUP INC (924K shares), EcoR1 Capital, LLC (795K shares), DEERFIELD MANAGEMENT CO (757K shares), Redmile Group, LLC (698K shares), Numeric Investors LLC (628K shares), and Tekla Capital Management LLC (530K shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.